Skip to main content

News

Learn More About Rivus and Our Pipeline Progress

Press Releases

2025

Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting^® 2025

Rivus Pharmaceuticals Provides Senior Leadership Update

Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trialof HU6 Showing Significant Reductions in Liver Fat in Patients with MASH

Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Out in MASH

Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology

Rivus Pharmaceuticals to Present Corporate Update at 2025 J.P. Morgan Healthcare Conference

2024

Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related Heart Failure

Rivus Pharmaceuticals to Present New Data from Phase 2a HuMAIN Trial of HU6 for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction at Heart Failure Society of America Annual Scientific Meeting 2024

Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O’Neil as Chief Financial Officer and Erin Lavelle as Director

Rivus Pharmaceuticals’ Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure

Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial Rationale and Design in European Journal of Heart FailureRivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6

2023

Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments

Phase 2a Study of HU6, Rivus Pharmaceuticals’ Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High BMI and Nonalcoholic Fatty Liver Disease

Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO

2022

Rivus Pharmaceuticals to Present Results from a Phase 2a Trial Evaluating its Controlled Metabolic Accelerator, HU6, at the American Association for the Study of Liver Diseases (AASLD)

Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardiometabolic Disorders

Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants

2021

Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardiometabolic Diseases

Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardiometabolic Diseases

Media Contact

info@rivuspharma.com

Contact Us

For general inquiries please e-mail us at info@rivuspharma.com.